Sionna Therapeutics Inc (SION)

$42.81 -0.89 (-2.04%)
Market Cap 1.95B
Revenue (ttm) 0.00
Net Income (ttm) -61.69M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 133,600
Avg Vol 304,776
Day's Range N/A - N/A
Shares Out 44.63M
Stochastic %K 52%
Beta N/A
Analysts Strong Sell
Price Target $45.71

Company Profile

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 819 2020
Address:
21 Hickory Drive, Suite 500, Waltham, United States
DerechosDelta
DerechosDelta Dec. 26 at 2:41 PM
$SION Trading behavior shows investors weighing repeatability of results above expansion claims. Capital allocation choices will reveal true priorities. Clear execution would attract broader institutional participation. Investors will likely reward proof above promises.
0 · Reply
JarvisFlow
JarvisFlow Dec. 23 at 4:08 PM
LifeSci Capital has updated their rating for Sionna Therapeutics ( $SION ) to Outperform with a price target of 60.
0 · Reply
dogDazeSummer
dogDazeSummer Dec. 18 at 8:56 PM
$IFRX Part 2 Hidden Gems according to Guggenheim (don’t shooot messanger): “….where AMGN’s avacopan could limited therapeutic window. IFRX has recently announced positive topline results from the Phase IIa 4-week basket study: (1) In HS, Izicopan demonstrated rapid & compelling efficacy that are aligned with successful biologic comparators, with clear safety and a dose-dependent profile; (2) In CSU, while the efficacy signal is stronger in HS,‘904 drives reduction in UAS7 within a range indicative of clinical activity. Given there is no other development in the oral C5aR space, IFRX could inaugurate a new MoA across this multibillion dollar indication market. Initiation of a Phase II program for Izicopan…. Also mentioned as hidden gems: $RAPT $PHAT $SION $FBRX
1 · Reply
BillionerOfKing
BillionerOfKing Dec. 12 at 11:55 PM
$SION Current Stock Price: $42.79
0 · Reply
theflynews
theflynews Dec. 1 at 9:37 PM
What You Missed On Wall Street On Monday - $SION - https://thefly.com/permalinks/entry.php/SIONid4248109?1764624879C38
0 · Reply
medguy
medguy Dec. 1 at 7:17 PM
Out with some gains thank you $SION love you
0 · Reply
CH_Expat
CH_Expat Dec. 1 at 6:40 PM
$ORKA $SION Very interested after a healthy correction.
0 · Reply
medguy
medguy Dec. 1 at 5:04 PM
Looking for a bounce $SION
0 · Reply
DARKP00L
DARKP00L Dec. 1 at 4:40 PM
$SION 11:21 on Dec. 01 2025 Sionna Therapeutics shares are trading lower after RBC Capital downgraded the stock from Sector Perform to Underperform. #tradeideas
0 · Reply
JarvisFlow
JarvisFlow Dec. 1 at 2:28 PM
RBC Capital has adjusted their stance on Sionna Therapeutics ( $SION ), setting the rating to Underperform with a target price of 24.
0 · Reply
Latest News on SION
Sionna Therapeutics, Inc. (SION) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 4, 2025, 11:28 AM EST - 25 days ago

Sionna Therapeutics, Inc. (SION) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Sionna Therapeutics to Participate in Upcoming December Investor Conferences

Nov 24, 2025, 7:00 AM EST - 5 weeks ago

Sionna Therapeutics to Participate in Upcoming December Investor Conferences

Sionna Therapeutics Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 7:00 AM EST - 7 weeks ago

Sionna Therapeutics Reports Third Quarter 2025 Financial Results

Sionna Therapeutics to Participate in Upcoming November Investor Conferences

Nov 4, 2025, 8:00 AM EST - 7 weeks ago

Sionna Therapeutics to Participate in Upcoming November Investor Conferences

Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference

Oct 24, 2025, 1:15 PM EDT - 2 months ago

Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference

Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis

Oct 21, 2025, 7:00 AM EDT - 2 months ago

Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference

Oct 1, 2025, 4:05 PM EDT - 3 months ago

Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference

Stock Picks From Seeking Alpha's August 2025 New Analysts

Sep 10, 2025, 9:00 AM EDT - 3 months ago

Stock Picks From Seeking Alpha's August 2025 New Analysts

ASML CLF ENPH ESEA FRSH FTK GDX

Sionna Therapeutics, Inc. (SION) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 11:13 AM EDT - 4 months ago

Sionna Therapeutics, Inc. (SION) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer

Sep 8, 2025, 8:00 AM EDT - 4 months ago

Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer

Sionna Therapeutics to Participate in Upcoming September Investor Conferences

Aug 27, 2025, 7:00 AM EDT - 4 months ago

Sionna Therapeutics to Participate in Upcoming September Investor Conferences

Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis

Aug 25, 2025, 7:00 AM EDT - 4 months ago

Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis

Sionna Therapeutics Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 7:00 AM EDT - 5 months ago

Sionna Therapeutics Reports Second Quarter 2025 Financial Results

Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model

Jun 6, 2025, 11:00 AM EDT - 7 months ago

Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model

Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

Jun 4, 2025, 7:00 AM EDT - 7 months ago

Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 3, 2025, 7:00 AM EDT - 7 months ago

Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference

May 22, 2025, 7:00 AM EDT - 7 months ago

Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference

Sionna Therapeutics Reports First Quarter 2025 Financial Results

May 12, 2025, 7:00 AM EDT - 8 months ago

Sionna Therapeutics Reports First Quarter 2025 Financial Results

Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025

Apr 30, 2025, 7:00 AM EDT - 8 months ago

Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025

Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 20, 2025, 7:00 AM EDT - 10 months ago

Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference

Feb 24, 2025, 8:00 AM EST - 11 months ago

Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference

Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 10, 2025, 4:03 PM EST - 11 months ago

Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO Week

Feb 8, 2025, 2:30 AM EST - 11 months ago

U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO Week

AARD AGH FBGL HCAI KRMN NPB ODYS

Sionna Therapeutics Prices Upsized Initial Public Offering

Feb 6, 2025, 7:51 PM EST - 11 months ago

Sionna Therapeutics Prices Upsized Initial Public Offering

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

Feb 1, 2025, 2:10 AM EST - 11 months ago

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

BBNX CSAI INR MAZE MTSR ODTX ODYS

Sionna Therapeutics Seeks $100 Million in IPO For Cystic Fibrosis Treatments

Jan 24, 2025, 1:45 PM EST - 1 year ago

Sionna Therapeutics Seeks $100 Million in IPO For Cystic Fibrosis Treatments

DerechosDelta
DerechosDelta Dec. 26 at 2:41 PM
$SION Trading behavior shows investors weighing repeatability of results above expansion claims. Capital allocation choices will reveal true priorities. Clear execution would attract broader institutional participation. Investors will likely reward proof above promises.
0 · Reply
JarvisFlow
JarvisFlow Dec. 23 at 4:08 PM
LifeSci Capital has updated their rating for Sionna Therapeutics ( $SION ) to Outperform with a price target of 60.
0 · Reply
dogDazeSummer
dogDazeSummer Dec. 18 at 8:56 PM
$IFRX Part 2 Hidden Gems according to Guggenheim (don’t shooot messanger): “….where AMGN’s avacopan could limited therapeutic window. IFRX has recently announced positive topline results from the Phase IIa 4-week basket study: (1) In HS, Izicopan demonstrated rapid & compelling efficacy that are aligned with successful biologic comparators, with clear safety and a dose-dependent profile; (2) In CSU, while the efficacy signal is stronger in HS,‘904 drives reduction in UAS7 within a range indicative of clinical activity. Given there is no other development in the oral C5aR space, IFRX could inaugurate a new MoA across this multibillion dollar indication market. Initiation of a Phase II program for Izicopan…. Also mentioned as hidden gems: $RAPT $PHAT $SION $FBRX
1 · Reply
BillionerOfKing
BillionerOfKing Dec. 12 at 11:55 PM
$SION Current Stock Price: $42.79
0 · Reply
theflynews
theflynews Dec. 1 at 9:37 PM
What You Missed On Wall Street On Monday - $SION - https://thefly.com/permalinks/entry.php/SIONid4248109?1764624879C38
0 · Reply
medguy
medguy Dec. 1 at 7:17 PM
Out with some gains thank you $SION love you
0 · Reply
CH_Expat
CH_Expat Dec. 1 at 6:40 PM
$ORKA $SION Very interested after a healthy correction.
0 · Reply
medguy
medguy Dec. 1 at 5:04 PM
Looking for a bounce $SION
0 · Reply
DARKP00L
DARKP00L Dec. 1 at 4:40 PM
$SION 11:21 on Dec. 01 2025 Sionna Therapeutics shares are trading lower after RBC Capital downgraded the stock from Sector Perform to Underperform. #tradeideas
0 · Reply
JarvisFlow
JarvisFlow Dec. 1 at 2:28 PM
RBC Capital has adjusted their stance on Sionna Therapeutics ( $SION ), setting the rating to Underperform with a target price of 24.
0 · Reply
JarvisFlow
JarvisFlow Nov. 19 at 10:13 AM
BTIG has adjusted their stance on Sionna Therapeutics ( $SION ), setting the rating to Buy with a target price of 50.
1 · Reply
d_risk
d_risk Nov. 5 at 4:19 PM
$SION - Sionna Therapeutics, Inc. - 10Q - Updated Risk Factors SION’s updated 10-Q risk factors stress heightened uncertainty in clinical trial outcomes, regulatory hurdles, post-approval safety, manufacturing and IP challenges, evolving healthcare laws, and fierce competition—while streamlining or removing detail on orphan drug incentives, personnel, and operational growth risks. #Biotechnology #HealthcareLaws #ManufacturingChallenges #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/SION/10-Q/2025-11-05
0 · Reply
shark1989
shark1989 Oct. 27 at 2:05 PM
$SION Looking for a 5% push today!
0 · Reply
S_Franconi
S_Franconi Oct. 22 at 1:11 PM
$SION Sionna’s ongoing clinical trials, including a Phase 1b trial for SION-451 combinations and a future Phase 2a trial for SION-719, are key catalysts that could validate their approach and potentially lead to significant market adoption. https://www.tipranks.com/news/ratings/buy-rating-for-sionna-therapeutics-innovative-cystic-fibrosis-treatments-with-promising-clinical-trials-ratings
1 · Reply
S_Franconi
S_Franconi Oct. 22 at 12:17 PM
$SION 46 Watchers. 10/22/25
0 · Reply
topstockalerts
topstockalerts Oct. 21 at 11:46 PM
Top Gainers PT2 $AMCI $BOF $SION $YDKG $NAUT
0 · Reply
topstockalerts
topstockalerts Oct. 21 at 8:13 PM
Top Gainers PT2 $AMCI $BOF $SION $RANI $AGRZ
0 · Reply
extrodyne
extrodyne Oct. 21 at 8:00 PM
$SION Big weekly change, closing at the top of the range. Could see a parabolic move tomorrow.
0 · Reply
patb99
patb99 Oct. 21 at 7:25 PM
$SION 😮
1 · Reply
DARKP00L
DARKP00L Oct. 21 at 5:26 PM
$SION 13:24 on Oct. 21 2025 Sionna Therapeutics shares are trading higher. The company initiated its PreciSION CF phase 2a proof-of-concept trial of SION-719. #tradeideas
0 · Reply
S_Franconi
S_Franconi Oct. 21 at 5:14 PM
$SION https://apps.cff.org/trials/pipeline/
0 · Reply
S_Franconi
S_Franconi Oct. 21 at 5:11 PM
$SION Thank you Sion!
0 · Reply